These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32054150)

  • 1. Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy.
    Lee J; Chang JS; Roh MR; Jung M; Lee CK; Oh BH; Chung KY; Koom WS; Shin SJ
    Cancer Res Treat; 2020 Jul; 52(3):730-738. PubMed ID: 32054150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
    Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
    Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
    Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
    Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
    van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
    Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
    Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
    Bolte LA; Lee KA; Björk JR; Leeming ER; Campmans-Kuijpers MJE; de Haan JJ; Vila AV; Maltez-Thomas A; Segata N; Board R; Harries M; Lorigan P; de Vries EGE; Nathan P; Fehrmann R; Bataille V; Spector TD; Hospers GAP; Weersma RK
    JAMA Oncol; 2023 May; 9(5):705-709. PubMed ID: 36795408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
    Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X
    Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
    Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
    Koch EAT; Petzold A; Dippel E; Erdmann M; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schell B; Terheyden P; Thoms KM; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
    Front Immunol; 2024; 15():1395225. PubMed ID: 38915414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for advanced melanoma: current situation in Japan.
    Kato J; Uhara H
    Jpn J Clin Oncol; 2021 Jan; 51(1):3-9. PubMed ID: 33140101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
    Loo K; Smithy JW; Postow MA; Betof Warner A
    Front Immunol; 2021; 12():810388. PubMed ID: 35087529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
    Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
    Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
    Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort.
    Remon J; Auclin E; Zubiri L; Schneider S; Rodriguez-Abreu D; Minatta N; Gautschi O; Aboubakar F; Muñoz-Couselo E; Pierret T; Rothschild SI; Cortiula F; Reynolds KL; Thibault C; Gavralidis A; Blais N; Barlesi F; Planchard D; Besse BMD
    ESMO Open; 2024 May; 9(5):103004. PubMed ID: 38653155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.